Clinical Trial Update: Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing immunogenicity and safety of BBIBP-Corv coadministered with PPV23 and IIV4 in dialysis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 in Adults Undergoing Hemodialysis

Drugs mentioned

• BBIBP-CorV
• IIV4 (inactivated influenza vaccine for quadrivalent formulation)
• PPV23 (pneumococcal polysaccharide vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: Hemolysis, COVID-19 | Phase 4 | Status: UNKNOWN